2025
Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies
Pulido-Saavedra A, Oliva H, Prudente T, Kitaneh R, Nunes E, Fogg C, Funaro M, Weleff J, Nia A, Angarita G. Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies. Cellular And Molecular Life Sciences 2025, 82: 49. PMID: 39833376, PMCID: PMC11747050, DOI: 10.1007/s00018-024-05519-2.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disorderPreclinical studiesClinical studiesReview of preclinical studiesConditioned place preferenceOpioid self-administrationEffects of psychedelicsPreclinical in vivo studiesOpioid use disorder treatmentFrequency of administrationPlace preferencePotential therapeutic effectsSelf-administrationWithdrawal symptomsPreclinical findingsMechanism of actionSafety profilePain studiesPsychedelicsMethodological quality assessmentClinical evidenceCardiovascular riskOpioidWeb of Science
2024
Associations Among Sleep, Pain, and Medications for Opioid Use Disorder: a Scoping Review
Hsaio C, DiMeola K, Jegede O, Funaro M, Langstengel J, Yaggi H, Barry D. Associations Among Sleep, Pain, and Medications for Opioid Use Disorder: a Scoping Review. Current Addiction Reports 2024, 11: 965-981. DOI: 10.1007/s40429-024-00606-7.Peer-Reviewed Original ResearchOpioid use disorderOUD severityUse disorderTreatment characteristicsOpioid use disorder treatment settingsTreatment of sleepDosing scheduleDisorder severityOpioidPainWeb of ScienceAssessed patientsCochrane LibraryMeasures of sleepMOUD treatmentCurrent evidenceMOUDSleepSleep disturbanceProvider preferencesPatientsStudy examined sleepDisordersTreatment settingsMedicationThe Impact of High-Potency Synthetic Opioids on Pharmacotherapies for Opioid Use Disorder: A Scoping Review
Jegede O, De Aquino J, Hsaio C, Caldwell E, Funaro M, Petrakis I, Muvvala S. The Impact of High-Potency Synthetic Opioids on Pharmacotherapies for Opioid Use Disorder: A Scoping Review. Journal Of Addiction Medicine 2024, 18: 499-510. PMID: 39356620, PMCID: PMC11449257, DOI: 10.1097/adm.0000000000001356.Peer-Reviewed Original ResearchNonmedical opioid useOpioid use disorderOpioid useWithdrawal symptomsTreatment outcomesSymptoms prior to treatmentUse disorderRisk of precipitated withdrawalLow-dose buprenorphineSynthetic opioidsPotency synthetic opioidsConclusions Current evidencePrecipitated withdrawalRisk of overdoseDosing strategiesPharmacological interactionsClinical significanceDecreased riskWeb of ScienceOpioidInclusion criteriaCurrent evidenceClinical implicationsMOUDPainA review of the kappa opioid receptor system in opioid use
Cayir S, Zhornitsky S, Barzegary A, Sotomayor-Carreño E, Sarfo-Ansah W, Funaro M, Matuskey D, Angarita G. A review of the kappa opioid receptor system in opioid use. Neuroscience & Biobehavioral Reviews 2024, 162: 105713. PMID: 38733895, DOI: 10.1016/j.neubiorev.2024.105713.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsKappa opioid receptor systemKappa-opioid receptorsOUD subjectsKappa-opioid receptor expressionOpioid withdrawal symptomsWithdrawal symptomsDynorphin levelsPeripheral blood lymphocytesOpioid useDrug-seeking/taking behaviorAnti-reward systemsKappa-opioid receptor antagonistClinical studiesCerebrospinal fluidOpioid receptor systemKOR/dynorphin systemDisorder subjectsOpioid receptorsOpioid intoxicationBlood lymphocytesReceptor systemOpioidWeb of ScienceClinical roleDynorphin